SCHEMBL10376281

SCHEMBL10376281

Cc1ccc(O)c(-c2cc(-c3ccccc3C(F)(F)F)n[nH]2)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.67
HPGD P15428 11/20 0.67
SMN1; SMN2 Q16637 9/20 0.67
NPSR1 Q6W5P4 4/20 0.67
CASP3 P42574 3/20 0.67
SENP8 Q96LD8 3/20 0.67
SENP7 Q9BQF6 3/20 0.67
SENP6 Q9GZR1 3/20 0.67
POLB P06746 1/20 0.67
KMT2A Q03164 14/20 0.67
MEN1 O00255 13/20 0.67
ALOX15 P16050 11/20 0.67
USP2 O75604 3/20 0.67
HSP90AA1 P07900 2/20 0.58
LMNA P02545 3/20 0.58
RAB9A P51151 10/20 0.57
NPC1 O15118 9/20 0.57
TP53 P04637 3/20 0.57
GLA P06280 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10358485 0.90 MAPT (0.61) MAPTHPGDSMN1; SMN2NPSR1CASP3
SCHEMBL10357577 0.86 MEN1 (0.53) MAPTHPGDSMN1; SMN2NPSR1CASP3
SCHEMBL10358038 0.85 KMT2A (0.79) MAPTHPGDSMN1; SMN2NPSR1CASP3
SCHEMBL10367183 0.84 KMT2A (0.66) MAPTHPGDSMN1; SMN2NPSR1CASP3
SCHEMBL10357921 0.84 MAPT (0.48) MAPTHPGDSMN1; SMN2NPSR1CASP3
SCHEMBL10358136 0.84 HPGD (0.55) MAPTHPGDSMN1; SMN2NPSR1CASP3
SCHEMBL10357267 0.83 MAPT (0.90) MAPTHPGDSMN1; SMN2NPSR1CASP3
SCHEMBL10357564 0.83 MEN1 (0.47) MAPTHPGDSMN1; SMN2NPSR1CASP3
SCHEMBL10372583 0.83 MAPT (0.65) MAPTHPGDSMN1; SMN2NPSR1CASP3
SCHEMBL10357282 0.83 KMT2A (0.89) MAPTHPGDSMN1; SMN2NPSR1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184583-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-19 US disclosed
US-20100144798-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-10 US disclosed
US-20100144798-A1 Modulators of ATP-Binding Cassette Transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184583-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 MAPT 4385/4885HPGD 1340/4885SMN1; SMN2 4852/4885
US-20100144798-A1 Modulators of ATP-Binding Cassette Transporters CFTR, ABCB1, ABCC2 MAPT 4385/4885HPGD 1340/4885SMN1; SMN2 4852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.